Nektar Therapeutics (NASDAQ:NKTR) SVP Stephen K. Doberstein sold 2,426 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $82.94, for a total value of $201,212.44. Following the completion of the sale, the senior vice president now directly owns 67,394 shares of the company’s stock, valued at approximately $5,589,658.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Shares of Nektar Therapeutics (NASDAQ NKTR) opened at $83.45 on Wednesday. The firm has a market capitalization of $13,381.02, a P/E ratio of -115.90 and a beta of 2.04. Nektar Therapeutics has a 52 week low of $12.50 and a 52 week high of $99.02. The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.99 and a current ratio of 4.14.
Several brokerages have issued reports on NKTR. BidaskClub lowered Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, February 8th. Zacks Investment Research raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Canaccord Genuity Group upped their target price on Nektar Therapeutics from $35.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, November 15th. Mizuho reaffirmed a “buy” rating and issued a $89.00 target price on shares of Nektar Therapeutics in a research note on Wednesday, February 14th. Finally, Cowen began coverage on Nektar Therapeutics in a research note on Tuesday, November 7th. They issued an “outperform” rating for the company. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $46.17.
Several large investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in shares of Nektar Therapeutics by 2.1% during the fourth quarter. BlackRock Inc. now owns 21,431,388 shares of the biopharmaceutical company’s stock valued at $1,279,883,000 after purchasing an additional 431,269 shares during the period. State Street Corp boosted its stake in shares of Nektar Therapeutics by 11.3% during the second quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock valued at $86,179,000 after purchasing an additional 447,023 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Nektar Therapeutics by 87.8% during the third quarter. Janus Henderson Group PLC now owns 3,329,281 shares of the biopharmaceutical company’s stock valued at $79,903,000 after purchasing an additional 1,556,352 shares during the period. First Trust Advisors LP boosted its stake in shares of Nektar Therapeutics by 3.0% during the fourth quarter. First Trust Advisors LP now owns 1,705,632 shares of the biopharmaceutical company’s stock valued at $101,860,000 after purchasing an additional 49,422 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Nektar Therapeutics by 1.0% during the fourth quarter. Geode Capital Management LLC now owns 1,445,971 shares of the biopharmaceutical company’s stock valued at $86,353,000 after purchasing an additional 13,958 shares during the period. 96.23% of the stock is owned by hedge funds and other institutional investors.
WARNING: This piece of content was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/21/nektar-therapeutics-nktr-svp-stephen-k-doberstein-sells-2426-shares-of-stock.html.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.